Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: Clinical screening in a large prospective cohort

AIDS

Volumn 17, Issue 12, 2003, Pages 1769-1785

  Barret, Béatrice ^a   Tardieu, Marc ^a   Rustin, Pierre ^b   Lacroix, Catherine ^c   Chabrol, Brigitte ^d   Desguerre, Isabelle ^e   Dollfus, Catherine ^f   Mayaux, Marie Jeanne ^a   Blanche, Stéphane ^e,g  

^a BICÊTRE HOSPITAL   (France)

^b INSERM   (France)

^c Serv d'Anatomopathologie Hop B   (France)

^d TIMONE HOSPITAL   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f ARMAND TROUSSEAU HOSPITAL   (France)

^g U d'Immunol Hematologie P   (France)

Author keywords

Children; HIV; Lamivudine; Mitochondria; Pregnancy toxicity; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; ZIDOVUDINE;

ALGORITHM; ARTICLE; CHILD; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERLACTATEMIA; INCIDENCE; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MASS SCREENING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERINATAL PERIOD; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; REGISTER; RESPIRATORY CHAIN; SYMPTOM;

ANTI-HIV AGENTS; BRAIN; CHI-SQUARE DISTRIBUTION; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MAGNETIC RESONANCE IMAGING; MICROSCOPY, ELECTRON; MITOCHONDRIA, MUSCLE; MITOCHONDRIAL DISEASES; MUSCLE, SKELETAL; PREGNANCY; PROSPECTIVE STUDIES; RISK FACTORS; ZIDOVUDINE;

EID: 0042232027     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200308150-00006     Document Type: Article

References (31)

1. Connor E.M, Sperling R.S, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type-1 with zidovudine treatment. N Engl J Med 1994, 331:1173-1180.
2. Taylor GP, Low-Beer N. Antiretroviral therapy in pregnancy. A focus on safety. Drug Safety 2001, 24:683-702.
3. Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell K, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 1999, 281:151-157.
4. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nature Med 1995, 5:417-422.
5. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999, 354: 1084-1089.
6. The Perinatal Safety review working group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 2000, 25:261-268.
7. Koren G, Pastuszak A, Itos S. Drugs in pregnancy. N Engl J Med 1998, 338:1128-1137.
8. Fleming TR. Evaluating the safety of intervention for prevention of perinatal transmission of HIV. Ann NY Acad Sci 2000, 918:201-211.
9. Blanche S, Rouzioux C, Moscato ML, Veber F, Mayaux MJ, Jacomet C, et al. A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. HIV Infection in Newborns French Collaborative Study Group. N Engl J Med 1989, 320:1643-1648.
10. Munnich A, Rötig A, Chrétien D, Cormier V, Bourgeron T, Bonnefont JP, et al. Clinical presentation of mitochondrial disorders in childhood. J Inher Metab Dis 1996, 19:521-527.
11. Brinkman K, Hadewych JM, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998, 12:1735-1744.
12. Engel AG, Franzini-Armstrong C. Myology Vol 1. New-York: McGraw-Hill Edts; 1994. pp. 832-888.
13. Karpati G. Structural and Molecular Basis of Skeletal Muscle Diseases. Basel: ISN Neuropath Press; 2002. pp. 202-211.
14. Rustin P, Chrétien D, Bourgeron T, Gérard B, Rotig A, Saudubray JM, et al. Biochemical molecular investigations in respiratory chain deficiency. Clin Chim Acta 1994, 228:35-51.
15. Rustin P, Chrétien D, Bourgeron D, Wucher A, Saudubray JM, Rotig A, et al. An improved representation of enzyme activities for assessment of the mitochondrial respiratory chain. Lancet 1991, 338:60.
16. Chrétien D, Gallego J, Barrientos A, Casademont J, Cardellach F, Munnich A, et al. The biochemical parameters for the diagnosis of respiratory chain deficiency in man and their lack of age-related changes. Biochem J 1997, 329:249-254.
17. Uusimaa J, Remes AM, Rantala H, Vainionpaa L, Herva R, Vuopala K, et al. Childhood encephalopathies and myopathies: a prospective study in a defined population to assess the frequency of mitochondrial disorders. Pediatrics 2000, 105: 598-603.
18. Darin N, Oldfors A, Moslemi AR, Holme E, Tulinius M. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities. Ann Neurol 2001, 49:377-383.
19. DiMauro S, Bonilla E, De Vivo DC. Does the patient have a mitochondrial encephalomyopathy? J Child Neurol 1999, 14:S23-35
20. Valanne L, Ketonen L, Majander A, Suomalainen A, Pihko H. Neuroradiologic findings in children with mitochondrial disorders. Am J Neuroradiol 1998, 19:369-377.
21. Haas RH. A comparison of genetic mitochondrial disease and nucleoside analogue toxicity. Does fetal nucleoside toxicity underlie reports of mitochondrial disease in infants born to women treated for HIV infection? Ann N Y Acad Sci 2000, 918:247-261.
22. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999, 283:442-450.
23. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990, 322:1098-1105.
24. Church JA, Mitchell WG, Gonzalez-Gomez I, Christensen J, Vu TH, Dimauro S. et al. Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. J Pediatr 2001, 138:748-751.
25. Gerschenson M, Erhart SW, Paik CY, St Claire MC, Nagashima K, Skopets B. et al. Fetal mitochondrial heart and skeletal muscle damage in erythrocebus patas monkeys exposed in utero to 3′-azido-3′-deoxythymidine. AIDS Res Hum Retrovir 2000, 16:635-644.
26. Ewings EL, Gerschenson M, St Claire MC, Nagashima K, Skopets B, Harbaugh SW, et al. Genotoxic and functional consequences of transplacental zidovudine exposure in fetal monkey brain mitochondria. J Acquir Immune Defic Syndr 2000, 24:100-105.
27. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zldovudine-induced myopathy. Lancet 1991, 337:508-510.
28. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L. et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002, 346:811-820.
29. Lim SE, Copeland WC. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase g. J Biol Chem 2001, 276:23616-23623.
30. Feng JY, Johnson AA, Johnson KA, Anderson KS. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem 2001, 276:23832-23837.
31. Walker UA, Seizer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002, 16:2165-2173.